Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Presbia PLC (LENS) Stock Price
Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.
A number of equities analysts have commented on the company. Zacks Investment Research raised Presbia PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Presbia PLC in a research note on Tuesday, May 23rd. Finally, Rodman & Renshaw reduced their target price on Presbia PLC from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, May 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Presbia PLC presently has a consensus rating of “Hold” and a consensus price target of $12.00.
Presbia PLC (NASDAQ LENS) traded down 1.48% during trading on Tuesday, hitting $2.66. The stock had a trading volume of 210 shares. Presbia PLC has a 12 month low of $1.86 and a 12 month high of $5.50. The stock has a 50 day moving average price of $2.41 and a 200-day moving average price of $2.87. The stock’s market cap is $45.10 million.
TRADEMARK VIOLATION WARNING: This report was originally reported by [[site]] and is owned by of [[site]]. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at [[permalink]].
Presbia PLC Company Profile
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.